<DOC>
	<DOC>NCT01473108</DOC>
	<brief_summary>Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.</brief_summary>
	<brief_title>Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862</brief_title>
	<detailed_description>Clinical pharmacology</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Fludrocortisone</mesh_term>
	<criteria>Healthy male white subjects 18 to 46 years of age Body mass index (BMI): 18 29.9 kg/mÂ² Clinically relevant findings in medical history or in the physical examination Systolic blood pressure below 100 or above 140 mmHg Diastolic blood pressure below 50 or above 90 mmHg Heart rate below 45 or above 95 beats / min</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Healthy volunteers, proof-of-concept trial, PK and PD</keyword>
</DOC>